In fact, TSC provides a good model into the roles of autophagy in human disease but also indicates the possibility of using autophagy inhibition as a therapeutic target, namely, in combination with mTORC1 inhibitors, as was also suggested for lymphangioleiomyomatosis (LAM) [26], a condition also associated with mTOR activation and TSC2 gene mutations. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.